Huw Nash Biography and Net Worth

COO of Stoke Therapeutics

Huw Nash is the chief operating officer and chief business officer of Stoke Therapeutics and was previously the founding chief executive officer. An entrepreneur-in-residence at Apple Tree Partners focused on novel therapeutics, Huw has 20 years of experience establishing, funding and growing startup biotechnology companies. Prior to Stoke, Huw was a co-founder and vice president of corporate development for Aileron Therapeutics. He was also a founding scientist of NeoGenesis Pharmaceuticals, where he served as vice president of external collaborations prior to the company’s acquisition by Schering-Plough. Huw received his B.A. in biochemical sciences from Harvard College and earned his Ph.D. in organic chemistry from Harvard University.

What is Huw M. Nash's net worth?: The estimated net worth of Huw M. Nash is at least $41,097.00 as of September 1st, 2021. Dr. Nash owns 5,700 shares of Stoke Therapeutics stock worth more than $41,097 as of March 29th. This net worth evaluation does not reflect any other investments that Dr. Nash may own. Additionally, Dr. Nash receives an annual salary of $429,670.00 as COO at Stoke Therapeutics. Learn More about Huw M. Nash's net worth.
How old is Huw M. Nash?: Dr. Nash is currently 57 years old. There are 7 older executives and no younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who is 75 years old. Learn More on Huw M. Nash's age.
What is Huw M. Nash's salary?: As the COO of Stoke Therapeutics, Inc., Dr. Nash earns $429,670.00 per year. There are 2 executives that earn more than Dr. Nash. The highest earning executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who commands a salary of $948,900.00 per year. Learn More on Huw M. Nash's salary.
How do I contact Huw M. Nash?: The corporate mailing address for Dr. Nash and other Stoke Therapeutics executives is 45 WIGGINS AVENUE, BEDFORD MA, 01730. Stoke Therapeutics can also be reached via phone at (781) 430-8200 and via email at ir@stoketherapeutics.com. Learn More on Huw M. Nash's contact information.
Has Huw M. Nash been buying or selling shares of Stoke Therapeutics?: Huw M. Nash has not been actively trading shares of Stoke Therapeutics during the last quarter. Most recently, Huw M. Nash sold 3,800 shares of the business's stock in a transaction on Monday, January 3rd. The shares were sold at an average price of $23.07, for a transaction totalling $87,666.00. Learn More on Huw M. Nash's trading history.
Who are Stoke Therapeutics' active insiders?: Stoke Therapeutics' insider roster includes Edward Kaye (), Huw Nash (COO), and Barry Ticho (Insider). Learn More on Stoke Therapeutics' active insiders.
Are insiders buying or selling shares of Stoke Therapeutics?: In the last twelve months, insiders at the sold shares 13 times. They sold a total of 5,626,881 shares worth more than $70,072,128.56. The most recent insider tranaction occured on March, 18th when Director Edward M Md Kaye sold 10,382 shares worth more than $90,011.94. Insiders at Stoke Therapeutics own 11.3% of the company. Learn More about insider trades at Stoke Therapeutics.
Information on this page was last updated on 3/18/2025.

Huw M. Nash Insider Trading History at Stoke Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/3/2022	Sell	3,800	$23.07	$87,666.00
12/1/2021	Sell	5,700	$24.44	$139,308.00
11/3/2021	Sell	1,900	$25.00	$47,500.00
11/1/2021	Sell	3,800	$23.54	$89,452.00
10/1/2021	Sell	5,700	$24.83	$141,531.00
9/1/2021	Sell	5,700	$26.00	$148,200.00	5,700
8/2/2021	Sell	5,700	$28.87	$164,559.00
1/6/2021	Sell	32	$57.14	$1,828.48
1/4/2021	Sell	5,700	$58.97	$336,129.00
12/18/2020	Sell	50,000	$60.00	$3,000,000.00	41,985
12/1/2020	Sell	5,700	$49.84	$284,088.00	5,700
11/10/2020	Sell	50,000	$45.00	$2,250,000.00
11/2/2020	Sell	5,700	$37.21	$212,097.00	5,700
10/1/2020	Sell	5,700	$34.54	$196,878.00	5,700
9/8/2020	Sell	30,718	$30.00	$921,540.00	30,718
9/1/2020	Sell	5,700	$27.74	$158,118.00	5,700
8/28/2020	Sell	2,081	$30.00	$62,430.00	2,081
7/16/2020	Sell	1,900	$25.06	$47,614.00	1,900
7/7/2020	Sell	913	$22.41	$20,460.33
7/1/2020	Sell	3,800	$23.15	$87,970.00	3,800
6/1/2020	Sell	2,107	$27.18	$57,268.26	2,107
3/2/2020	Sell	49,143	$25.89	$1,272,312.27	6,324

See Full Table

Huw M. Nash Buying and Selling Activity at Stoke Therapeutics

Stoke Therapeutics Company Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $7.21

$7.06

$7.48

50 Day Range

MA: $9.32

$7.21

$12.74

2 Week Range

Now: $7.21

$7.06

$17.58

Volume

572,399 shs

Average Volume

724,092 shs

Market Capitalization

$389.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Huw Nash Biography and Net Worth

What is Huw M. Nash's net worth?

How old is Huw M. Nash?

What is Huw M. Nash's salary?

How do I contact Huw M. Nash?

Has Huw M. Nash been buying or selling shares of Stoke Therapeutics?

Who are Stoke Therapeutics' active insiders?

Are insiders buying or selling shares of Stoke Therapeutics?